Page 51 - MemoriaCIBER-2017ENG
P. 51
Clinical Guides
• Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al 2017 ESC/EACTS Guide- lines for the management of valvular heart disease Eur Heart J 2017 Sep 21;38(36):2739- 2791
• Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, et al 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/ kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia Eur Heart J 2017 Oct 16
• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al Case-based imple- mentation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Eur Heart J 2018 Jan 14;39(3):e1-e33
• Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, et al Clinical Trial Principles and Endpoint De nitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement Eur Heart J 2017 Apr 18
• Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, et al Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease Eur Heart J 2017 Sep 14;38(35):2649-2662
• Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on propro- tein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk Eur Heart J 2017 Aug 1;38(29):2245-2255
• Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, et al Global position paper on cardiovascular regenerative medicine (Transnational Alliance for Regener- ative Therapies in Cardiovascular Syndromes) Eur Heart J 2017 Sep 1;38(33):2532-2546
• Badimon L, Bugiardini R, Cenko E, Cubedo J, Dorobantu M, Duncker DJ, et al Position paper of the European Society of Cardiology-working group of coronary pathophysiology and micro- circulation: obesity and heart disease Eur Heart J 2017 Jul 1;38(25):1951-1958
• Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis Eur Heart J 2017 Jun 7;38(22):1710-1716
• Corrà U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA, et al Role of cardiopulmonary exercise testing in clinical strati cation in heart failure A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 2018 Jan;20(1):3-15
• Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Piérard LA, et al Standards de ning a ‘Heart Valve Centre’: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint Eur Heart J 2017 Jul 21;38(28):2177-2183
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovas- cular toxicity of the European Society of Cardiology (ESC) Eur J Heart Fail 2017 Jan;19(1):9-42
• Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, et al Clinical practice of contrast echocardiography: recommendation by the European Association of Cardio- vascular Imaging (EACVI) 2017 Eur Heart J Cardiovasc Imaging 2017 Nov 1;18(11):1205-1205af
